We serve Chemical Name:2-AMINO-2′-FLUOROBENZOPHENONE CAS:1581-13-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-AMINO-2′-FLUOROBENZOPHENONE
CAS.NO:1581-13-1
Synonyms:2-Amino-2′-fluorobenzophenone;NRAJMXHXQHCBHO-UHFFFAOYSA;2′-fluoro-2-aminobenzophenone
Molecular Formula:C13H10FNO
Molecular Weight:215.22300
HS Code:2922399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:401.9ºC at 760mmHg
Density:1.236g/cm3
Index of Refraction:1.609
PSA:43.09000
Exact Mass:215.07500
LogP:3.22010
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Amino-2′-fluorobenzophenone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2′-fluoro-2-aminobenzophenone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2′-fluoro-2-aminobenzophenone Use and application,2-Amino-2′-fluorobenzophenone technical grade,usp/ep/jp grade.
Related News: With rising demand and approvals required for new drugs, an external collaboration with CDMOs helps in driving a successful and robust clinical development plan for a new drug molecule. ethyl (E)-3-(3,3-dimethyl-2,3-dihydro-1,3-thiasilol-4-yl)acrylate manufacturers Recipharm joined the COVID-19 fight in December, signing on to produce the Moderna vaccine at its plant in Monts, France. The company hasn’t revealed if the new facilities will be engaged in COVID-19 vaccine production, though the plant in Morocco will “mirror” a new fill-finish line it added in France. 3,3-Dimethyl-glutardialdehyd-(2,4-dinitro-phenyl)-hydrazon suppliers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. 2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)ethoxy]-N,N-diethylethanamine,hydrochloride vendor & factory The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005.,The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005.
